Cargando…

Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility

BACKGROUND: Patients in intensive care units receive many drugs simultaneously but through limited venous accesses. Several intravenous therapies have to be administered through the same catheter, thus increasing the risk of physicochemical incompatibility. The purpose of this work was to assess and...

Descripción completa

Detalles Bibliográficos
Autores principales: Foinard, Aurélie, Décaudin, Bertrand, Barthélémy, Christine, Debaene, Bertrand, Odou, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407719/
https://www.ncbi.nlm.nih.gov/pubmed/22794308
http://dx.doi.org/10.1186/2110-5820-2-28
_version_ 1782239375902375936
author Foinard, Aurélie
Décaudin, Bertrand
Barthélémy, Christine
Debaene, Bertrand
Odou, Pascal
author_facet Foinard, Aurélie
Décaudin, Bertrand
Barthélémy, Christine
Debaene, Bertrand
Odou, Pascal
author_sort Foinard, Aurélie
collection PubMed
description BACKGROUND: Patients in intensive care units receive many drugs simultaneously but through limited venous accesses. Several intravenous therapies have to be administered through the same catheter, thus increasing the risk of physicochemical incompatibility. The purpose of this work was to assess and to quantify the impact of physical incompatibility on the mass flow rates of drugs infused simultaneously to the patient, through an in vitro study. METHODS: Furosemide-midazolam incompatibility was used to assess the impact of physical incompatibility on drug mass flow rates. Furosemide, midazolam, and saline were simultaneously infused. A filter was added at the end of the infusion line to retain visible particles. Two infusion conditions were tested with and without visible particles. A partial least square method on UV spectra was used to determine simultaneously the concentrations of the two drugs at the egress of the terminal extension line. The drug mass flow rate (expressed as mg/h) was calculated as the product of drug concentration versus total flow rate. Observed/theoretical mass flow rate ratios for each drug (%) were determined per infusion condition. RESULTS: Even in the absence of visible particles, precipitation of furosemide led to a drug loss estimated at between 10% and 15%. Furosemide is more impacted by interaction because the pH of the mixture is acid and this form is poorly soluble in an aqueous solution. CONCLUSIONS: Physical incompatibility between furosemide and midazolam leads to a significant reduction in drug delivered to the patient and may result in treatment failure.
format Online
Article
Text
id pubmed-3407719
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-34077192012-08-08 Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility Foinard, Aurélie Décaudin, Bertrand Barthélémy, Christine Debaene, Bertrand Odou, Pascal Ann Intensive Care Research BACKGROUND: Patients in intensive care units receive many drugs simultaneously but through limited venous accesses. Several intravenous therapies have to be administered through the same catheter, thus increasing the risk of physicochemical incompatibility. The purpose of this work was to assess and to quantify the impact of physical incompatibility on the mass flow rates of drugs infused simultaneously to the patient, through an in vitro study. METHODS: Furosemide-midazolam incompatibility was used to assess the impact of physical incompatibility on drug mass flow rates. Furosemide, midazolam, and saline were simultaneously infused. A filter was added at the end of the infusion line to retain visible particles. Two infusion conditions were tested with and without visible particles. A partial least square method on UV spectra was used to determine simultaneously the concentrations of the two drugs at the egress of the terminal extension line. The drug mass flow rate (expressed as mg/h) was calculated as the product of drug concentration versus total flow rate. Observed/theoretical mass flow rate ratios for each drug (%) were determined per infusion condition. RESULTS: Even in the absence of visible particles, precipitation of furosemide led to a drug loss estimated at between 10% and 15%. Furosemide is more impacted by interaction because the pH of the mixture is acid and this form is poorly soluble in an aqueous solution. CONCLUSIONS: Physical incompatibility between furosemide and midazolam leads to a significant reduction in drug delivered to the patient and may result in treatment failure. Springer 2012-07-13 /pmc/articles/PMC3407719/ /pubmed/22794308 http://dx.doi.org/10.1186/2110-5820-2-28 Text en Copyright ©2012 Foinard et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Foinard, Aurélie
Décaudin, Bertrand
Barthélémy, Christine
Debaene, Bertrand
Odou, Pascal
Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility
title Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility
title_full Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility
title_fullStr Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility
title_full_unstemmed Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility
title_short Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility
title_sort impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407719/
https://www.ncbi.nlm.nih.gov/pubmed/22794308
http://dx.doi.org/10.1186/2110-5820-2-28
work_keys_str_mv AT foinardaurelie impactofphysicalincompatibilityondrugmassflowratesexampleoffurosemidemidazolamincompatibility
AT decaudinbertrand impactofphysicalincompatibilityondrugmassflowratesexampleoffurosemidemidazolamincompatibility
AT barthelemychristine impactofphysicalincompatibilityondrugmassflowratesexampleoffurosemidemidazolamincompatibility
AT debaenebertrand impactofphysicalincompatibilityondrugmassflowratesexampleoffurosemidemidazolamincompatibility
AT odoupascal impactofphysicalincompatibilityondrugmassflowratesexampleoffurosemidemidazolamincompatibility